Skip to main content

Sanofi receives FDA approval for Gaucher disease pill ahead of Dupixent expiry

BioPharma Dive reports that Sanofi has secured FDA approval for Infilbray, a treatment for Gaucher disease. The decision follows a lengthy development process and arrives as Sanofi prepares for the end of patent protection on its top-selling drug, Dupixent.

This approval is important for Sanofi’s product pipeline and revenue outlook. For pharma executives, it signals the need to plan for patent cliffs and diversify income sources. The industry will monitor how quickly Infilbray is adopted and how competitors respond.

BioPharma Dive

Find out more here